Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of $(18.24) per share from the same period last year. The company reported quarterly sales of $515.03 thousand which beat the analyst consensus estimate of $390.00 thousand by 32.06 percent. This is a 64.06 percent decrease over sales of $1.43 million the same period last year.
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of $(18.24) per share from the same period last year. The company reported quarterly sales of $515.03 thousand which beat the analyst consensus estimate of $390.00 thousand by 32.06 percent. This is a 64.06 percent decrease over sales of $1.43 million the same period last year.
Ensysce Biosciences(納斯達克股票代碼:ENSC)公佈的季度虧損爲每股1.13美元,比分析師普遍預期的0.87美元(0.87美元)低29.89%。這比去年同期每股虧損18.24美元(18.24美元)增長了93.8%。該公司公佈的季度銷售額爲515,030美元,比分析師普遍預期的39萬美元高出32.06%。這比去年同期的143萬美元銷售額下降了64.06%。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧